Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,821.91 +1,021.07 (+1.63%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Vincerx Pharma, Inc. (VINC)
After hours:
| Previous close | 0.9300 |
| Open | 0.9272 |
| Bid | 0.8611 x 200 |
| Ask | 0.8838 x 200 |
| Day's range | 0.8550 - 0.9350 |
| 52-week range | 0.6100 - 9.3720 |
| Volume | |
| Avg. volume | 1,208,267 |
| Market cap | 25.904M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.
- Benzinga
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
On Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024. VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options. Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule: The Q3W schedule is well tolerated with no dose-limiting toxicity (DLT)
- GuruFocus.com
Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look
Comparing Vincerx Pharma's Performance Against Analyst Estimates
